XOMAP | XOMA Corporation Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	25.69 - 26.17
52 Week Range	24.87 - 26.51
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	5,324
Average Volume	1,629
Shares Outstanding	11,952,900
Market Cap	307,189,530
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-12-16

Valuation
Profitability
Growth
Health
P/E Ratio	25.67
Forward P/E Ratio	N/A
EPS	1.00
1YR Price Target	N/A
Dividend Yield	8.31%
Dividend Per Share	2.14
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	13
Country	USA
Website	XOMAP

XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

XOMAP's peers: POWWP, STRRP, XOMAO, FBIOP, FRGAP, OTRKP, RILYP

*Chart delayed

Analyzing fundamentals for XOMAP we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is on medium level and Health is very weak. For more detailed analysis please see XOMAP Fundamentals page.

Watching at XOMAP technicals we can see that long-term trend is bullish, while middle-term trend is bearish, but short-term trend is bullish. More technicals details can be found on XOMAP Technicals page.